PAUL RONALD SANBERG
Pilots at Pilot Country Dr, Brooksville, FL

6734215, May 11, 2004

Jun 15, 2001

09/882935

Douglas Shytle - Lutz FL
Paul Sanberg - Spring Hill FL
Mary Newman - Valrico FL
Archie A. Silver - Tampa FL

University of South Florida - Tampa FL

A61K 3113

514661

Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), Tourettes Syndrome, and neuropsychiatric disorders (such as bipolar disorder, depression, an anxiety disorder, schizophrenia, a seizure disorder, Parkinsons disease and attention deficit hyperactivity disorder).

2009001, Jan 15, 2009

Jul 7, 2008

12/168608

Paul R. Sanberg - Spring Hill FL, US
Sylvia Gografe - Nashville TN, US

UNIVERSITY OF SOUTH FLORIDA - Tampa FL

A61K 35/12, A61P 43/00

424 937

A method of treating a fetus or embryo suspected of having a congenital condition that involves an abnormal or missing protein, the method has the steps of a. providing a plurality of human umbilical cord blood in a form suitable for intravenous administration; a b. administering the human umbilical cord blood cells to a mother carrying a fetus of embryo suspected of having said congenital condition. Such congenital conditions include Sanfilippo's syndrome, Hunter's syndrome, Hurler's syndrome, Tay-Sachs disease, Gaucher's disease, von Gierke's disease, Pompes disease, Cori disease, Andersen disease, McArdle's disease, Hers disease, Tauri's disease or Type IX glycogen storage disease.

2008028, Nov 13, 2008

May 9, 2008

12/118675

Paul R. Sanberg - Spring Hill FL, US
Robert W. Engelman - Tampa FL, US
William R. Gower - Seffner FL, US

UNIVERSITY OF SOUTH FLORIDA - Tampa FL

A61K 38/02, A61P 29/00

514 2

A method for purifying an immunosuppressant protein (HISP) has the steps of obtaining supernatant from hNT cells; exposing the supernatant to preparative polyacrylamide gel electrophoresis to produce 20 isoelectric fractions, including active isoelectric fraction #10; placing the active isoelectric fraction on a Blue Sepharose column to bind albumin; and collecting the free fraction containing the concentrated, isolated HISP. Also disclosed is a method of treating inflammation, using an effective amount of an HISP. The HISP is anionic, has a molecular weight of 40-100 kDa, an isoelectric point of about 4.8 and is obtained from the supernatant of hNT cells, but not from NCCIT embryonal carcinoma cells. T98G glioblastoma cells or THP-1 monocytic leukemia cells. HISP can maintain T cells in a quiescent G.sub.0/G.sub.1 state without lowering their viability. HISP loses activity when treated with heat, pH2, pH11, or mixed with trypsin or carboxypeptidase, but not with neuraminidase. HISP can suppress proliferation of responder peripheral blood mononuclear cells in allogeneic mixed lymphocyte cultures; HISP can suppress T-cell proliferation and IL-2 production in response to phorbol 12-myristate 13-acetate (PMA), ionomycin and concanavalin-A. HISP does not bind to heparin-sepharose CL-B gel; or to albumin-binding resin Blue Sepharose, HISP is concentrated with YM10 ultrafiltration. HISP does not act through the T-cell receptor-CD3 complex or via altered accessory signal cells. A method of treating inflammation comprises administering an effective amount of hNT neuronal cells.

5834001, Nov 10, 1998

May 24, 1995

8/449214

Keith E. Dionne - Rehoboth MA
Dwaine F. Emerich - Providence RI
Diane Hoffman - Cambridge MA
Paul R. Sanberg - Spring Hill FL
Lisa Christenson - New Haven CT
Orion D. Hegre - Green Valley AZ
David W. Sharp - St. Louis MO
Paul E. Lacy - Webster Grove MO
Patrick Aebischer - Lutry, CH
Alfred V. Vasconcellos - Cranston RI
Michael J. Lysaght - Greenwich RI
Frank T. Gentile - Warwich RI

Brown University Research Foundation

A61K 950, A61K 914

424422

A method of forming an implantable and retrievable immunoisolatory vehicle is disclosed, the method comprising the steps of first forming a jacket of biocompatible thermoplastic or hydrogel, and then loading the jacket with a core comprising a volume of at least 1. mu. l and at least 10. sup. 4 cells capable of secreting a biocompatible matrix comprising a hydrogel or extracellular matrix, said jacket having a molecular weight cutoff permitting passage of molecules thereacross to provide said biologically active product or said function.

5798113, Aug 25, 1998

May 24, 1995

8/449524

Keith E. Dionne - Rehoboth MA
Dwaine F. Emerich - Providence RI
Diane Hoffman - Cambridge MA
Paul R. Sanberg - Spring Hill FL
Lisa Christenson - New Haven CT
Orion D. Hegre - Green Valley AZ
David W. Scharp - St. Louis MO
Paul E. Lacy - Webster Grove MO
Patrick Aebischer - Lutry, CH
Michael J. Lysaght - Greenwich RI
Frank T. Gentile - Warwich RI

Brown University Research Foundation

A61K 950, A61K 914

424422

A method of providing a biologically active molecule or metabolic or immunologic function to a patient, comprising implanting into the body of the patient at least one immunoisolatory vehicle comprising a core comprising a volume in excess of 1. mu. l and at least about 10. sup. 4 living cells dispersed in a biocompatible matrix formed of a hydrogel or extracellular matrix components, said cells being capable of secreting a biologically active product or of providing a metabolic or immunologic function to the patient; and an external jacket surrounding said core, said jacket being formed from a thermoplastic or hydrogel, said jacket being free of said cells projecting externally therefrom, said jacket being biocompatible and having a molecular weight cutoff permitting passage of molecules between the patient and the core through said jacket to provide said biologically active product of function.

6034079, Mar 7, 2000

Nov 23, 1998

9/198882

Paul R. Sanberg - Spring Hill FL
Roland D. Shytle - Lutz FL
Archie A. Silver - Tampa FL

University of South Florida - Tampa FL

A61K 3154, A61K 31505, A61K 31445, A61K 3113

5142258

Nicotine-responsive neuropsychiatric disorders can be treated by administering a nicotine antagonist, particularly mecamylamine. Combination therapy of mecamylamine with a neuroleptic drug also is disclosed. The neuropsychiatric disorders include Tourette's syndrome, schizophrenia, depression, bipolar disorder, tremors, attention deficit hyperactivity disorder, obsessive-compulsive disorder, hemidystonia, rage outbursts and tardive dyskinesia.

5702700, Dec 30, 1997

Mar 13, 1995

8/402389

Paul R. Sanberg - Spring Hill FL
Don F. Cameron - Lutz FL
Cesario V. Borlongan - Lutz FL

University of South Florida - Tampa FL

A01N 6300, A61K 3552, A61K 3822

424 931

A method of generating in situ trophic factor production by transplanting Sertoli cells into the central nervous system of a mammal, the cells creating trophic factors in situ.

8309352, Nov 13, 2012

Nov 9, 2006

11/558411

Paul Sanberg - Spring Hill FL, US
Juan Sanchez-Ramos - Tampa FL, US
Alison Willing - Tampa FL, US
Daniel D. Richard - Sedona AZ, US

University of South Florida - Tampa FL

C12N 5/00, C12N 5/02, C12N 5/071

435377, 435325, 435366, 435383, 435384

The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.

2006014, Jun 29, 2006

Feb 7, 2006

11/349455

Doug Shytle - Lutz FL, US
Jun Tah - Tampa FL, US
Paul Sanberg - Spring Hill FL, US

A61K 38/54, A61K 31/13

514002000, 514663000

Novel therapeutic targets in the treatment of neuroimmunological and neurodegenerative disorders. Accordingly, methods of treating a neurodegenerative disorder in a patient, as well as inhibiting the release of a proinflammatory cytokine, comprising the step of contacting a target cell with a therapeutically effective amount of a cholinergic agonist, such as those chosen from the group consisting of acetycholine, nicotine, choline, galantamine, cytisine, GTS-21, or derivatives thereof, wherein the target cell is a microglia is provided.

6083523, Jul 4, 2000

Sep 4, 1998

9/148671

Keith E. Dionne - Rehoboth MA
Dwaine F. Emerich - Providence RI
Diane Hoffman - Cambridge MA
Paul R. Sanberg - Spring Hill FL
Lisa Christenson - New Haven CT
Orion D. Hegre - Green Valley AZ
David W. Scharp - St. Louis MO
Paul E. Lacy - Webster Grove MO
Patrick Aebischer - Lutry, CH
Alfred V. Vasconcellos - Cranston RI
Michael J. Lysaght - Greenwich RI
Frank T. Gentile - Warwich RI

Brown University Research Foundation - Providence RI
Brown University - Providence RI

A61F 202

424424

An immunoisolatory vehicle for the implantation into an individual of cells which produce a needed product or provide a needed metabolic function. The vehicle is comprised of a core region containing isolated cells and materials sufficient to maintain the cells, and a permselective, biocompatible, peripheral region free of the isolated cells, which immunoisolates the core yet provides for the delivery of the secreted product or metabolic function to the individual.